Emory University

In this Healio video exclusive, Jonathan H. Kim, MD, provides an overview of the recently published scientific statement on clinical considerations for participation of athletes with heart disease in competitive sports.

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated insulin delivery system, according to findings from the SECURE-T2D trial.

Treatment with immune checkpoint inhibitors appeared linked with higher risk for venous thromboembolism among adults with metastatic lung cancer, according to study results presented at CHEST Annual Meeting.

Sudden cardiac death among athletes, both recreational and master level, remains a public health issue, disparately affecting players of certain sports and athlete demographics, researchers reported.

According to published results, glucagon-like peptide-1 agonists may not be associated with increased complications for patients with diabetes who undergo total hip arthroplasty.

Results presented at the American Society for Surgery of the Hand Annual Meeting showed patient-reported outcome measures were significantly improved after cubital tunnel release regardless of electrodiagnostic diagnosis.

In this video from the Academic Orthopaedic Consortium Business & Leadership Symposium, Scott D. Boden, MD, discusses ways to achieve an effective and sustainable, market competitive compensation plan.

Clinicians could benefit significantly if medical institutions began billing patients for electronic messages; however, ethical implications of the practice, which include erecting another potential barrier to care, complicate the issue.

Low heart rate variability during times of mental stress may be an indicator of stress-induced myocardial ischemia for patients with stable CAD, according to a study published in Circulation: Cardiovascular Imaging.

CHICAGO — The addition of abemaciclib to fulvestrant extended PFS for patients with advanced breast cancer whose disease progressed on prior cyclin-dependent kinase 4/6 inhibitor therapy, according to data presented at ASCO Annual Meeting.